Mind Medicine (MindMed) Inc
MNMD12.290USD
-1.910-13.45%
Fechamento 11/03, 16:00（ET）Cotações atrasadas em 15 min
931.62MValor de mercado
PerdaP/L TTM
Mais detalhes de Mind Medicine (MindMed) Inc Empresa
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Informações de Mind Medicine (MindMed) Inc
Código da empresaMNMD
Nome da EmpresaMind Medicine (MindMed) Inc
Data de listagemMay 04, 2015
CEOMr. Robert (Rob) Barrow
Número de funcionários74
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
EndereçoOne World Trade Center
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Telefone12122206633
Sitehttps://ir.mindmed.co/
Código da empresaMNMD
Data de listagemMay 04, 2015
CEOMr. Robert (Rob) Barrow
Executivos da empresa Mind Medicine (MindMed) Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Outro
79.04%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Outro
79.04%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
22.81%
Hedge Fund
16.77%
Investment Advisor
13.84%
Research Firm
1.64%
Individual Investor
1.03%
Bank and Trust
0.36%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Outro
43.15%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
383
42.48M
55.83%
-5.92M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
5.22M
6.86%
+17.02K
+0.33%
Jun 30, 2025
Commodore Capital LP
5.00M
6.57%
+475.00K
+10.50%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.71%
--
--
Jun 30, 2025
Marshall Wace LLP
3.42M
4.5%
+828.07K
+31.93%
Jun 30, 2025
Driehaus Capital Management, LLC
3.09M
4.06%
-258.75K
-7.72%
Jun 30, 2025
Deep Track Capital LP
2.50M
3.29%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.13M
2.8%
-888.00K
-29.42%
Jun 30, 2025
State Street Investment Management (US)
1.81M
2.37%
-36.32K
-1.97%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
2.37%
+47.45K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.28%
+66.66K
+4.00%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
AdvisorShares Psychedelics ETF
10.44%
SPDR S&P Pharmaceuticals ETF
1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.17%
iShares U.S. Pharmaceuticals ETF
0.33%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
Vanguard US Momentum Factor ETF
0.07%
Nuveen ESG Small-Cap ETF
0.06%
Ver Mais
AdvisorShares Psychedelics ETF
Proporção10.44%
SPDR S&P Pharmaceuticals ETF
Proporção1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.17%
iShares U.S. Pharmaceuticals ETF
Proporção0.33%
iShares Micro-Cap ETF
Proporção0.19%
ProShares Ultra Nasdaq Biotechnology
Proporção0.09%
Invesco Nasdaq Biotechnology ETF
Proporção0.09%
Vanguard US Momentum Factor ETF
Proporção0.07%
Nuveen ESG Small-Cap ETF
Proporção0.06%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Data
Tipo
Proporção
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
